Logo image of IRON

DISC MEDICINE INC (IRON) Stock Price, Forecast & Analysis

USA - NASDAQ:IRON - US2546041011 - Common Stock

89.95 USD
+2.91 (+3.34%)
Last: 11/14/2025, 8:00:02 PM
89.95 USD
0 (0%)
After Hours: 11/14/2025, 8:00:02 PM

IRON Key Statistics, Chart & Performance

Key Statistics
Market Cap3.13B
Revenue(TTM)N/A
Net Income(TTM)-181.11M
Shares34.77M
Float27.60M
52 Week High95.95
52 Week Low30.82
Yearly DividendN/A
Dividend YieldN/A
EPS(TTM)-5.35
PEN/A
Fwd PEN/A
Earnings (Next)02-25 2026-02-25/amc
IPO2020-08-12
Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryBiotechnology


IRON short term performance overview.The bars show the price performance of IRON in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 20 40 60 80

IRON long term performance overview.The bars show the price performance of IRON in the last 1, 2 and 3 years. 1 year 2 years 3 years 20 40 60

The current stock price of IRON is 89.95 USD. In the past month the price increased by 0.01%. In the past year, price increased by 51.28%.

DISC MEDICINE INC / IRON Daily stock chart

IRON Latest News, Press Relases and Analysis

IRON Competitors/Peers

The largest stocks on the US markets in the "Biotechnology" sub-industry
Full List
Symbol
Company Name
TA
FA
PE
Market Cap
ABBV ABBVIE INC 24.59 410.48B
AMGN AMGEN INC 15.4 181.29B
GILD GILEAD SCIENCES INC 15.26 155.13B
VRTX VERTEX PHARMACEUTICALS INC 25.18 112.08B
REGN REGENERON PHARMACEUTICALS 15.41 73.50B
ALNY ALNYLAM PHARMACEUTICALS INC 880.71 58.88B
INSM INSMED INC N/A 40.84B
NTRA NATERA INC N/A 28.04B
BIIB BIOGEN INC 10.01 24.56B
UTHR UNITED THERAPEUTICS CORP 17.67 21.10B
INCY INCYTE CORP 16.22 20.34B
NBIX NEUROCRINE BIOSCIENCES INC 34.66 14.37B

About IRON

Company Profile

IRON logo image Disc Medicine, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery, development, and commercialization of treatments for hematologic diseases. The company is headquartered in Watertown, Massachusetts and currently employs 84 full-time employees. The company went IPO on 2020-08-12. The firm's pipeline includes bitopertin for the treatment of erythropoietic porphyrias (Eps), including erythropoietic protoporphyria (EPP) and X-linked protoporphyria (XLP), and Diamond-Blackfan Anemia (DBA); DISC-0974 for the treatment of anemia of myelofibrosis (MF), and anemia of chronic kidney disease (CKD), and DISC-3405 (formerly MWTX-003) for the treatment of polycythemia vera (PV) and other hematologic disorders. In addition, its preclinical programs also include DISC-0998, for the treatment of anemia associated with inflammatory diseases. Bitopertin is the lead product candidate in the Company's heme biosynthesis modulation portfolio. The company is developing DISC-3405, a monoclonal antibody against Transmembrane Serine Protease 6 that it licensed from Mabwell Therapeutics, Inc.

Company Info

DISC MEDICINE INC

321 Arsenal Street, Suite 101

Watertown MASSACHUSETTS US

Employees: 84

IRON Company Website

IRON Investor Relations

Phone: 16176749274

DISC MEDICINE INC / IRON FAQ

Can you describe the business of DISC MEDICINE INC?

Disc Medicine, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery, development, and commercialization of treatments for hematologic diseases. The company is headquartered in Watertown, Massachusetts and currently employs 84 full-time employees. The company went IPO on 2020-08-12. The firm's pipeline includes bitopertin for the treatment of erythropoietic porphyrias (Eps), including erythropoietic protoporphyria (EPP) and X-linked protoporphyria (XLP), and Diamond-Blackfan Anemia (DBA); DISC-0974 for the treatment of anemia of myelofibrosis (MF), and anemia of chronic kidney disease (CKD), and DISC-3405 (formerly MWTX-003) for the treatment of polycythemia vera (PV) and other hematologic disorders. In addition, its preclinical programs also include DISC-0998, for the treatment of anemia associated with inflammatory diseases. Bitopertin is the lead product candidate in the Company's heme biosynthesis modulation portfolio. The company is developing DISC-3405, a monoclonal antibody against Transmembrane Serine Protease 6 that it licensed from Mabwell Therapeutics, Inc.


Can you provide the latest stock price for DISC MEDICINE INC?

The current stock price of IRON is 89.95 USD. The price increased by 3.34% in the last trading session.


Does DISC MEDICINE INC pay dividends?

IRON does not pay a dividend.


How is the ChartMill rating for DISC MEDICINE INC?

IRON has a ChartMill Technical rating of 9 out of 10 and a ChartMill Fundamental rating of 2 out of 10.


Where is DISC MEDICINE INC (IRON) stock traded?

IRON stock is listed on the Nasdaq exchange.


When does DISC MEDICINE INC (IRON) report earnings?

DISC MEDICINE INC (IRON) will report earnings on 2026-02-25, after the market close.


What is the ownership structure of DISC MEDICINE INC (IRON)?

You can find the ownership structure of DISC MEDICINE INC (IRON) on the Ownership tab.


IRON Technical Analysis

ChartMill assigns a technical rating of 9 / 10 to IRON. When comparing the yearly performance of all stocks, IRON is one of the better performing stocks in the market, outperforming 92.99% of all stocks.


Chartmill TA Rating
Chartmill Setup Rating

IRON Fundamental Analysis

ChartMill assigns a fundamental rating of 2 / 10 to IRON. IRON scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

IRON Financial Highlights

Over the last trailing twelve months IRON reported a non-GAAP Earnings per Share(EPS) of -5.35. The EPS decreased by -36.83% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -28.73%
ROE -31.59%
Debt/Equity 0.05
Chartmill High Growth Momentum
EPS Q2Q%-98.88%
Sales Q2Q%N/A
EPS 1Y (TTM)-36.83%
Revenue 1Y (TTM)N/A

IRON Forecast & Estimates

18 analysts have analysed IRON and the average price target is 111.09 USD. This implies a price increase of 23.5% is expected in the next year compared to the current price of 89.95.


Analysts
Analysts85.56
Price Target111.09 (23.5%)
EPS Next Y-43.36%
Revenue Next YearN/A

IRON Ownership

Ownership
Inst Owners89.69%
Ins Owners0.45%
Short Float %9.76%
Short Ratio6.29